FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2216565528> ?p ?o ?g. }

• W2216565528 endingPage "3676" @default.
• W2216565528 startingPage "3662" @default.
• W2216565528 abstract "// Elizabeth M. Matthew 1,2,* , Lanlan Zhou 1,2,* , Zhaohai Yang 3 , David T. Dicker 1,2 , Sheldon L. Holder 4 , Bora Lim 1,4,6 , Ramdane Harouaka 5 , Si-Yang Zheng 5 , Joseph J. Drabick 4 , Nicholas E. Lamparella 4 , Cristina I. Truica 4 and Wafik S. El-Deiry 1,2 1 Laboratory of Translational Oncology and Experimental Cancer Therapeutics, Division of Hematology-Oncology, Penn State Hershey Cancer Institute, Hershey, PA, USA 2 Laboratory of Translational Oncology and Experimental Cancer Therapeutics, Department of Medical Oncology and Molecular Therapeutics Program, Fox Chase Cancer Center, Philadelphia, PA, USA 3 Department of Pathology, Penn State Milton S. Hershey Medical Center, Hershey, PA, USA 4 Division of Hematology-Oncology, Penn State Milton S. Hershey Medical Center and Penn State Hershey Cancer Institute, Hershey, PA, USA 5 Department of Biomedical Engineering, Penn State University, University Park, PA, USA 6 The University of Texas MD Anderson Cancer Center, Houston, TX, USA * These authors have contributed equally to this work Correspondence to: Wafik S. El-Deiry , email: // Keywords : circulating tumor cells (CTCs), carcinoma of unknown primary (CUP), immunofluorescence, diagnosis Received : November 14, 2015 Accepted : November 23, 2015 Published : December 18, 2015 Abstract Real-time, single-cell multiplex immunophenotyping of circulating tumor cells (CTCs) is hypothesized to inform diagnosis of tissue of origin in patients with carcinoma of unknown primary (CUP). In 20 to 50% of CUP patients, the primary site remains unidentified, presenting a challenge for clinicians in diagnosis and treatment. We developed a post-CellSearch CTC assay using multiplexed Q-dot or DyLight conjugated antibodies with the goal of detecting multiple markers in single cells within a CTC population. We adapted our approach to size-based CTC enrichment protocols for capturing CTCs and subsequent immunofluorescence (IF) using a minimal set of markers to predict the primary sites for common metastatic tumors. The carcinomas are characterized with cytokeratin 7 (CK7), cytokeratin 20 (CK20), thyroid transcription factor 1 (TTF-1), estrogen receptor (ER) or prostate-specific antigen (PSA. IF has been optimized in cultured tumor cells with individual antibodies, then with conjugated antibodies to form a multiplex antibody set. With IF, we evaluated antibodies specific to these 5 markers in lung, breast, colorectal, and prostate cancer cell lines and blood from metastatic prostate and breast cancer patients. This advanced technology provides a noninvasive, diagnostic blood test as an adjunct to routine tissue biopsy. Its further implementation requires prospective clinical testing." @default.
• W2216565528 created "2016-06-24" @default.
• W2216565528 creator A5018176156 @default.
• W2216565528 creator A5019403402 @default.
• W2216565528 creator A5023976873 @default.
• W2216565528 creator A5036882735 @default.
• W2216565528 creator A5040899413 @default.
• W2216565528 creator A5044635619 @default.
• W2216565528 creator A5052750238 @default.
• W2216565528 creator A5053047745 @default.
• W2216565528 creator A5053893309 @default.
• W2216565528 creator A5075201353 @default.
• W2216565528 creator A5083051783 @default.
• W2216565528 creator A5090228232 @default.
• W2216565528 date "2015-12-18" @default.
• W2216565528 modified "2023-09-26" @default.
• W2216565528 title "A multiplexed marker-based algorithm for diagnosis of carcinoma of unknown primary using circulating tumor cells" @default.
• W2216565528 cites W1965067847 @default.
• W2216565528 cites W1967162936 @default.
• W2216565528 cites W1981989535 @default.
• W2216565528 cites W1987368604 @default.
• W2216565528 cites W1990120645 @default.
• W2216565528 cites W199986378 @default.
• W2216565528 cites W2014629508 @default.
• W2216565528 cites W2016356101 @default.
• W2216565528 cites W2027366995 @default.
• W2216565528 cites W2033416556 @default.
• W2216565528 cites W2043966026 @default.
• W2216565528 cites W2047130151 @default.
• W2216565528 cites W2047481883 @default.
• W2216565528 cites W2048452946 @default.
• W2216565528 cites W2060688862 @default.
• W2216565528 cites W2060872914 @default.
• W2216565528 cites W2063140987 @default.
• W2216565528 cites W2078904004 @default.
• W2216565528 cites W2080264320 @default.
• W2216565528 cites W2087528996 @default.
• W2216565528 cites W2095761465 @default.
• W2216565528 cites W2111976640 @default.
• W2216565528 cites W2117098158 @default.
• W2216565528 cites W2119494825 @default.
• W2216565528 cites W2127869062 @default.
• W2216565528 cites W2128019596 @default.
• W2216565528 cites W2138933035 @default.
• W2216565528 cites W2143806098 @default.
• W2216565528 cites W2148703808 @default.
• W2216565528 cites W2150760649 @default.
• W2216565528 cites W2161862739 @default.
• W2216565528 cites W2163473969 @default.
• W2216565528 cites W2167481707 @default.
• W2216565528 cites W257606270 @default.
• W2216565528 doi "https://doi.org/10.18632/oncotarget.6657" @default.
• W2216565528 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4826160" @default.
• W2216565528 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/26695546" @default.
• W2216565528 hasPublicationYear "2015" @default.
• W2216565528 type Work @default.
• W2216565528 sameAs 2216565528 @default.
• W2216565528 citedByCount "25" @default.
• W2216565528 countsByYear W22165655282016 @default.
• W2216565528 countsByYear W22165655282017 @default.
• W2216565528 countsByYear W22165655282018 @default.
• W2216565528 countsByYear W22165655282019 @default.
• W2216565528 countsByYear W22165655282021 @default.
• W2216565528 countsByYear W22165655282022 @default.
• W2216565528 crossrefType "journal-article" @default.
• W2216565528 hasAuthorship W2216565528A5018176156 @default.
• W2216565528 hasAuthorship W2216565528A5019403402 @default.
• W2216565528 hasAuthorship W2216565528A5023976873 @default.
• W2216565528 hasAuthorship W2216565528A5036882735 @default.
• W2216565528 hasAuthorship W2216565528A5040899413 @default.
• W2216565528 hasAuthorship W2216565528A5044635619 @default.
• W2216565528 hasAuthorship W2216565528A5052750238 @default.
• W2216565528 hasAuthorship W2216565528A5053047745 @default.
• W2216565528 hasAuthorship W2216565528A5053893309 @default.
• W2216565528 hasAuthorship W2216565528A5075201353 @default.
• W2216565528 hasAuthorship W2216565528A5083051783 @default.
• W2216565528 hasAuthorship W2216565528A5090228232 @default.
• W2216565528 hasBestOaLocation W22165655281 @default.
• W2216565528 hasConcept C121608353 @default.
• W2216565528 hasConcept C126322002 @default.
• W2216565528 hasConcept C143998085 @default.
• W2216565528 hasConcept C194409129 @default.
• W2216565528 hasConcept C2779013556 @default.
• W2216565528 hasConcept C61238886 @default.
• W2216565528 hasConcept C71924100 @default.
• W2216565528 hasConceptScore W2216565528C121608353 @default.
• W2216565528 hasConceptScore W2216565528C126322002 @default.
• W2216565528 hasConceptScore W2216565528C143998085 @default.
• W2216565528 hasConceptScore W2216565528C194409129 @default.
• W2216565528 hasConceptScore W2216565528C2779013556 @default.
• W2216565528 hasConceptScore W2216565528C61238886 @default.
• W2216565528 hasConceptScore W2216565528C71924100 @default.
• W2216565528 hasIssue "4" @default.
• W2216565528 hasLocation W22165655281 @default.
• W2216565528 hasLocation W22165655282 @default.
• W2216565528 hasLocation W22165655283 @default.
• W2216565528 hasLocation W22165655284 @default.
• W2216565528 hasOpenAccess W2216565528 @default.

• next